Inflammatory breast cancer outcomes by breast cancer subtype: a population-based study
- PMID: 30378451
- DOI: 10.2217/fon-2018-0677
Inflammatory breast cancer outcomes by breast cancer subtype: a population-based study
Abstract
Aim: To assess the outcomes of breast cancer subtype in inflammatory breast cancer (IBC).
Methods: We retrospectively assessed IBC patients from the SEER program.
Results: We identified 626 patients, including 230 (36.7%),100 (17.6%), 113 (18.1%), and 173 (27.6%) patients with HoR+/HER2-, HoR+/HER2+, HoR-/HER2+, and HoR-/HER2- subtype disease, respectively. Multivariate analysis demonstrated that, using HoR+/HER2- subtype as reference, patients with HoR+/HER2+ subtype had better breast cancer-specific survival (BCSS) and overall survival (OS), and patients with HoR-/HER2- subtype had worse BCSS and OS, while BCSS and OS were comparable for HoR-/HER2+ subtype. Similar trends were observed in patients who received surgery, radiotherapy, chemotherapy or trimodality therapy.
Conclusion: Breast cancer subtype is clinically useful for predicting survival outcome in IBC. The HoR+/HER2- subtype shows poorer survival outcome than HoR+/HER2+ subtype.
Keywords: SEER; inflammatory breast cancer; prognosis; subtype; survival; treatment.
Similar articles
-
Marital status is an independent prognostic factor in inflammatory breast cancer patients: an analysis of the surveillance, epidemiology, and end results database.Breast Cancer Res Treat. 2019 Nov;178(2):379-388. doi: 10.1007/s10549-019-05385-8. Epub 2019 Aug 14. Breast Cancer Res Treat. 2019. PMID: 31414242 Free PMC article.
-
Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.Oncotarget. 2017 Jul 25;8(30):49370-49379. doi: 10.18632/oncotarget.17217. Oncotarget. 2017. PMID: 28472761 Free PMC article.
-
Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis.BMC Cancer. 2021 Feb 6;21(1):138. doi: 10.1186/s12885-021-07855-z. BMC Cancer. 2021. PMID: 33549037 Free PMC article.
-
Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer.Surg Clin North Am. 2018 Aug;98(4):787-800. doi: 10.1016/j.suc.2018.03.009. Epub 2018 May 24. Surg Clin North Am. 2018. PMID: 30005774 Review.
-
Predictive factors on outcomes in metaplastic breast cancer.Breast Cancer Res Treat. 2017 Oct;165(3):499-504. doi: 10.1007/s10549-017-4367-5. Epub 2017 Jul 8. Breast Cancer Res Treat. 2017. PMID: 28689362 Review.
Cited by
-
Marital status and survival of patients with colorectal signet ring cell carcinoma: a population-based study.Sci Rep. 2020 Oct 21;10(1):17881. doi: 10.1038/s41598-020-74720-7. Sci Rep. 2020. PMID: 33087758 Free PMC article.
-
Construction and Validation of Nomograms for Predicting Overall Survival and Cancer-Specific Survival in Nonmetastatic Inflammatory Breast Cancer Patients Receiving Tri-Modality Therapy: A Population-Based Study.Med Sci Monit. 2019 Dec 2;25:9167-9178. doi: 10.12659/MSM.919458. Med Sci Monit. 2019. PMID: 31789307 Free PMC article.
-
Marital status is an independent prognostic factor in inflammatory breast cancer patients: an analysis of the surveillance, epidemiology, and end results database.Breast Cancer Res Treat. 2019 Nov;178(2):379-388. doi: 10.1007/s10549-019-05385-8. Epub 2019 Aug 14. Breast Cancer Res Treat. 2019. PMID: 31414242 Free PMC article.
-
Toward precision medicine in inflammatory breast cancer.Transl Cancer Res. 2019 Oct;8(Suppl 5):S469-S478. doi: 10.21037/tcr.2019.05.04. Transl Cancer Res. 2019. PMID: 35117125 Free PMC article. Review.
-
Systematic Review and Meta-Analysis of Treatment Effects on Survival in Patients with Inflammatory Breast Cancer.Asian Pac J Cancer Prev. 2023 Oct 1;24(10):3335-3343. doi: 10.31557/APJCP.2023.24.10.3335. Asian Pac J Cancer Prev. 2023. PMID: 37898836 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
